Abbott Laboratories (NYSE:ABT)‘s stock had its “buy” rating restated by equities research analysts at Stifel Nicolaus in a note issued to investors on Friday. They currently have a $58.00 price objective on the healthcare product maker’s stock. Stifel Nicolaus’ price target would suggest a potential upside of 14.08% from the stock’s previous close.

Several other equities research analysts also recently issued reports on ABT. Zacks Investment Research downgraded Abbott Laboratories from a “hold” rating to a “sell” rating in a report on Tuesday, March 28th. Cowen and Company restated a “buy” rating and set a $48.00 price objective on shares of Abbott Laboratories in a report on Thursday, April 13th. Jefferies Group LLC dropped their price objective on Abbott Laboratories from $52.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, April 18th. UBS AG restated a “neutral” rating and set a $41.00 price objective on shares of Abbott Laboratories in a report on Tuesday, April 18th. Finally, Morgan Stanley restated an “equal weight” rating and set a $42.00 price objective on shares of Abbott Laboratories in a report on Wednesday, April 19th. Four research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $51.80.

Abbott Laboratories (NYSE ABT) traded down 0.02% during mid-day trading on Friday, hitting $50.84. 7,980,202 shares of the company were exchanged. The stock has a market cap of $88.22 billion, a price-to-earnings ratio of 52.90 and a beta of 1.07. The firm has a 50 day moving average price of $48.18 and a 200 day moving average price of $44.68. Abbott Laboratories has a 12 month low of $37.38 and a 12 month high of $51.13.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, July 20th. The healthcare product maker reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.02. Abbott Laboratories had a return on equity of 14.91% and a net margin of 6.74%. The company had revenue of $6.64 billion for the quarter, compared to the consensus estimate of $6.63 billion. During the same period in the previous year, the business earned $0.55 EPS. Abbott Laboratories’s revenue for the quarter was up 24.5% compared to the same quarter last year. Analysts anticipate that Abbott Laboratories will post $2.48 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Abbott Laboratories’ (ABT) “Buy” Rating Reaffirmed at Stifel Nicolaus” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/21/abbott-laboratories-abt-buy-rating-reaffirmed-at-stifel-nicolaus.html.

In related news, insider Joseph J. Manning sold 4,200 shares of the business’s stock in a transaction that occurred on Wednesday, April 26th. The stock was sold at an average price of $43.95, for a total transaction of $184,590.00. Following the completion of the transaction, the insider now owns 26,224 shares in the company, valued at approximately $1,152,544.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jared Watkin sold 552 shares of the business’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $47.97, for a total value of $26,479.44. Following the transaction, the insider now owns 47,090 shares of the company’s stock, valued at approximately $2,258,907.30. The disclosure for this sale can be found here. Insiders have sold a total of 206,902 shares of company stock valued at $9,497,761 in the last 90 days. Insiders own 0.76% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Banco Santander S.A. bought a new position in Abbott Laboratories during the fourth quarter worth about $5,189,000. Perceptive Advisors LLC bought a new position in Abbott Laboratories during the fourth quarter worth about $1,921,000. L & S Advisors Inc bought a new position in Abbott Laboratories during the fourth quarter worth about $468,000. Whittier Trust Co. raised its position in Abbott Laboratories by 1.7% in the first quarter. Whittier Trust Co. now owns 401,048 shares of the healthcare product maker’s stock worth $17,807,000 after buying an additional 6,751 shares in the last quarter. Finally, Marshwinds Advisory Co. raised its position in Abbott Laboratories by 118.2% in the first quarter. Marshwinds Advisory Co. now owns 66,576 shares of the healthcare product maker’s stock worth $2,957,000 after buying an additional 36,069 shares in the last quarter. Institutional investors and hedge funds own 71.02% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Analyst Recommendations for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.